Toronto Dominion Bank Affimed N.V. Transaction History

Toronto Dominion Bank

  • $55.7 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Feb 14, 2024
BUY
$0.46 - $0.65 $131 - $185
285 New
285 $0
Q3 2023

Nov 14, 2023
BUY
$0.46 - $0.65 $131 - $185
285 New
285 $0

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Toronto Dominion Bank Portfolio

Follow Toronto Dominion Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

News

Stay updated on Toronto Dominion Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email